Roseburia

A genus of Gram-positive, obligate anaerobic, flagellated bacteria within the lachnospiraceae family that ranks among the most important butyrate producers in the human gut. Key species include R. intestinalis and R. hominis. Roseburia is consistently depleted across inflammatory, metabolic, and neurodegenerative diseases, and its sensitivity to metal stress places it at the center of the gut metal microbiome axis.

Butyrate Production and Anti-inflammatory Mechanisms

  • Produces butyrate as its primary fermentation end-product from dietary fiber, particularly via the butyryl-CoA:acetate CoA-transferase pathway [1].
  • Butyrate from Roseburia acts through multiple anti-inflammatory pathways:
  • HDAC inhibition: butyrate inhibits histone deacetylases in colonocytes and immune cells, promoting anti-inflammatory gene expression and Treg differentiation.
  • GPR109A signaling: butyrate activates the GPR109A receptor on colonic epithelial cells and dendritic cells, inducing IL-10 production and suppressing NF-kB-mediated inflammation.
  • Barrier maintenance: supports tight junction integrity (ZO-1, occludin, claudin-1) and maintains colonocyte oxygen consumption, preserving the anaerobic lumen.
  • Flagellin from R. hominis specifically activates TLR5 signaling in a beneficial context, promoting mucosal immune homeostasis rather than inflammation [2].

Depletion Across Disease States

Roseburia depletion is among the most reproducible microbiome findings in human disease:

  • Cardiovascular disease: depleted in ACVD patients in the Jie et al. study; CAG4 containing Faecalibacterium and Roseburia was closely related to 10 serum metabolite modules and important for maintaining normal coronary physiology [3] [4] [5].
  • Hypertension: bidirectional Mendelian randomization links reduced Roseburia to elevated blood pressure [6].
  • IBD: reduced in both Crohn's disease and ulcerative colitis; inversely correlated with disease activity scores [7].
  • Multiple sclerosis: depleted alongside other lachnospiraceae members; loss reduces SCFA-mediated immune modulation [8].
  • Colorectal cancer: reduced; butyrate loss diminishes anti-tumorigenic HDAC inhibition in colonocytes [9] [10].
  • Type 2 diabetes: depleted; inversely correlated with HbA1c and insulin resistance.
  • Chronic kidney disease: depleted across CKD progression, contributing to loss of SCFA-mediated renal protection [11] [12] [13].
  • Endometriosis: Roseburia sp. CAG:45 decreased in endometriosis [14].
  • Parkinson's disease: depleted alongside other SCFA producers as part of the metal-driven dysbiosis framework [15] [16] [17].
  • Schizophrenia: Roseburia is significantly depleted in schizophrenia patients (p=0.023), and its abundance is negatively correlated with fMRI regional homogeneity (ReHo) indices in the right superior temporal cortex, right middle temporal cortex, and left cuneus — brain regions showing decreased ReHo in schizophrenia [2].

Metal Sensitivity

  • Roseburia is particularly sensitive to heavy metal stress, more so than many other gut commensals.
  • Iron-sulfur cluster enzymes in the butyrate synthesis pathway are vulnerable to disruption by cadmium, lead, and other toxic metals that compete for iron binding sites.
  • Under metal-stressed conditions, Roseburia is outcompeted by siderophore-producing enterobacteriaceae that aggressively scavenge iron, compounding its depletion.
  • This metal sensitivity positions Roseburia as an early biomarker for environmental metal exposure effects on the gut microbiome.

Key Metabolites

  • Butyrate — primary output; HDAC inhibitor, colonocyte fuel, Treg inducer.
  • Acetate — secondary fermentation product; feeds acetogenic pathways.
  • Formate — minor product; serves as electron carrier in anaerobic cross-feeding.
  • Flagellin — immunostimulatory protein from R. hominis that promotes beneficial TLR5 signaling.

Key Sources

Connections

  • lachnospiraceae — parent family; Roseburia is a flagship genus
  • faecalibacterium prausnitzii — co-depleted partner; together represent the core butyrate-producing guild
  • ruminococcus — receives starch degradation products from R. bromii for butyrate conversion
  • cardiovascular disease — CAG4 (Faecalibacterium/Roseburia) loss correlated with CAD severity
  • crohns disease — depleted; inversely correlated with disease activity
  • colorectal cancer — butyrate loss reduces HDAC-mediated tumor suppression
  • parkinsons disease — depleted in metal-driven dysbiosis framework
  • iron — Fe-S clusters essential for butyrate production; iron competition from pathogens
  • cadmium — particularly sensitive to Cd-induced depletion
  • dysbiosis — one of the most reliably depleted genera across disease states
  • inflammation — butyrate/HDAC/GPR109A anti-inflammatory axis
  • gut metal microbiome — metal sensitivity makes it an early indicator of metal-induced dysbiosis

References (17)

  1. Fiona C. Ross, Dhrati Patangia, Ghjuvan Grimaud et al. (2024). The interplay between diet and the gut microbiome: implications for health and disease. Nature Reviews Microbiology
  2. Li S, Song J, Ke P et al. (2021). The Gut Microbiome is Associated with Brain Structure and Function in Schizophrenia. Scientific Reports. doi:10.1038/s41598-021-89166-8
  3. Zhuye Jie, Huihua Xia, Shi-Long Zhong et al. (2017). The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications. doi:10.1038/s41467-017-00900-1
  4. Honghong Liu, Xi Chen, Xiaomin Hu et al. (2019). Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. doi:10.1186/s40168-019-0683-9
  5. Catia Almeida, J. Guilherme Goncalves-Nobre, Diogo Alpuim Costa et al. (2023). The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?. Frontiers in Gastroenterology. doi:10.3389/fgstr.2023.1235126
  6. Yihui Li, Ru Fu, Ruixuan Li et al. (2023). Causality of gut microbiome and hypertension: A bidirectional mendelian randomization study. Frontiers in Cardiovascular Medicine. doi:10.3389/fcvm.2023.1167346
  7. Li H, Christman LM, Li R et al. (2020). Synergic Interactions between Polyphenols and Gut Microbiota in Mitigating Inflammatory Bowel Diseases. Food & Function. doi:10.1039/D0FO00713G
  8. Léo Boussamet, Emmanuel Montassier, Camille Mathé et al. (2024). Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study. Scientific Reports. doi:10.1038/s41598-024-57949-4
  9. Kishore Vipperla, Stephen J. O'Keefe (2016). Diet, microbiota, and dysbiosis: a 'recipe' for colorectal cancer. Food & Function
  10. Lena Van Dingenen, Charlotte Segers, Shari Wouters et al. (2023). Dissecting the Role of the Gut Microbiome and Fecal Microbiota Transplantation in Radio- and Immunotherapy Treatment of Colorectal Cancer. Frontiers in Cellular and Infection Microbiology
  11. Tang, Lai, Bhatt (2023). Tang et al. 2023 — Gut Microbiome Tango with CKD Progression. Journal of Translational Medicine. doi:10.1186/s12967-023-04455-2
  12. Yasuno, Nakahama, Kurogi et al. (2024). Yasuno et al. 2024 — Dysbiosis of Gut Microbiota in CKD. Internal Medicine. doi:10.2169/internalmedicine.1602-23
  13. Zhang, Liao, Mei et al. (2023). Zhang 2023 — Metagenome-Wide Analysis of ESRD Microbiome and Uremic Toxins. Genome Biology. doi:10.1186/s13059-023-03056-y
  14. Perez-Prieto I, Vargas E, Salas-Espejo E et al. (2024). Gut microbiome in endometriosis: a cohort study on 1000 individuals. BMC Medicine. doi:10.1186/s12916-024-03503-y
  15. ★Karen Pendergrass (2025). Microbial Metallomics and Parkinson's Disease: A Unified Metal-Driven Framework Linking Ferroptosis, Dysbiosis, and alpha-Synuclein Pathology. Conference Presentation. doi:10.5281/zenodo.17830083
  16. Madelyn C Houser, Malú G Tansey (2019). Houser 2019 -- Microbiome and Inflammation in Parkinson's Disease Progression. npj Parkinson's Disease
  17. Timothy R Sampson, Andrew S Neish (2024). Sampson 2024 -- A Microbiome Signature of Parkinson's Disease. Communications Medicine

Related Articles